Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. "Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection," said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts' average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly's global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly's sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly's biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company's "patent cliff" will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. "We haven't wasted the crisis," Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. "We're more agile, we're leaner and I believe we're better operators today." Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company's longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly's Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly "to go back on offense", helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago. Claim: Lilly's quarterly sales largely offset Cymbalta slide.

A: Drugmaker Eli Lilly and Co's quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs.
****
Q: Paragraph: A nurse prepares a bottle of donated milk for a baby at Son Dureta's Hospital in Palma de Mallorca, Spain March 10, 2006. REUTERS/Dani Cardona The chemical bisphenol A, or BPA, is commonly used in plastic food and beverage containers and in the coating of food cans. Until now, environmental and consumer activists who have questioned the safety of BPA have relied on animal studies. But the study by British researchers in the Journal of the American Medical Association found that among 1,455 U.S. adults, those with the highest levels of BPA were more likely to have heart disease, diabetes and liver-enzyme abnormalities than those with the lowest levels. U.S. Food and Drug Administration officials said they would review the new findings, which were not yet published when the agency issued a draft conclusion in August that BPA is safe at current exposure levels. "We have confidence in the data that we've looked at and the data that we're relying on to say that the margin of safety is adequate," FDA official Laura Tarantino said at a meeting of experts advising the agency on whether it made the right call. "There are things you can do if you choose to reduce your level of bisphenol A," Tarantino said. "But we have not recommended that anyone change their habits or change their use of any of these products because right now we don't have the evidence in front of us to suggest that people need to." Panel chairman Martin Philbert declined to say what the committee's next move would be. BPA is used to make polycarbonate plastic, a clear shatter-resistant material in products ranging from baby bottles to medical devices. BPA can mimic the hormone estrogen in the body. People can consume BPA when it leaches out of the plastic into baby formula, water or food inside a container. Some retailers and manufacturers are moving away from products with BPA. Canadian officials have concluded BPA was harmful. Steven Hentges of the American Chemistry Council, an industry group, said the study's design did not allow for anyone to conclude BPA causes heart disease and diabetes. "On the other hand, though, bisphenol A has been very intensively studied in a very large number of laboratory animal studies. And the weight of evidence from those studies ... continues to support the safe use of products containing bisphenol A," he said in a telephone interview. The British researchers, who acknowledged their findings are not proof that the chemical is causing the harm, analyzed urine samples from a U.S. government health survey of adults ages 18-74 representative of the U.S. population. The 25 percent of people with the highest levels of bisphenol A in their bodies were more than twice as likely to have heart disease, including heart attacks or type 2 diabetes, compared to the 25 percent with the lowest levels. At the FDA panel meeting, several scientists and activists said the FDA ignored animal studies finding health concerns and some called for the chemical to be banned in food containers. Democratic U.S. Rep. John Dingell of Michigan, who heads the House Committee on Energy and Commerce, said the FDA has "focused myopically on industry-funded research." Iowa Republican Sen. Chuck Grassley, ranking member of the Committee on Finance, released a letter he wrote to FDA Commissioner Dr. Andrew von Eschenbach asking why the agency has not appointed a safety panel to review BPA. Tarantino said nothing was ignored but industry-funded studies finding no harm were important in the conclusions. The panel is expected to present its advice to the FDA next month. Tarantino, head of the FDA's office of food additive safety, said there is talk of government scientists doing their own BPA safety studies, but that could take years to conduct. Claim: Common plastics chemical linked to heart problems.

A: A major study links a chemical widely used in plastic products, including baby bottles, to health problems in humans like heart disease and diabetes, but U.S. regulators said on Tuesday they still believe it is safe.
****
Q: Paragraph: On 3 May 2018, the "Occupy Democrats" Facebook page posted a meme which claimed that the president had violated the constitutional separation of church and state by setting up a "religious office": President Trump did sign an executive order in May 2018 to establish a new faith-based initiative within the White House, but nobody from his administration called it a "religious office" that description appears to have come from Occupy Democrats. Furthermore, Trump's initiative represents significant continuity of, rather than a departure from, the previous two administrations. Although every detail and working of the new initiative has not yet been outlined, it certainly does not represent a radical change. Trump's White House Faith and Opportunity Initiative bears a striking resemblance to the White House Office of Faith-Based and Community Initiatives, which George W. Bush set up in 2001, and which Barack Obama continued during his administration but renamed the White House Office of Faith-Based and Neighborhood Partnerships. In brief, Trump's executive order which he signed on 3 May 2018, the National Day of Prayer replaces the White House Office of Faith-Based and Neighborhood Partnerships with the White House Faith and Opportunity Initiative, keeping it within the Executive Office of the President of the United States. The executive order also sets out the following: Beyond that, Trump's order is somewhat vague on the exact workings of the initiative and the duties of the advisor who will lead it: One potentially significant provision in the executive order calls for those in charge of the Faith and Opportunity Initiative to contact the Attorney General if they see potential executive branch violations of a religious liberty memorandum published by Attorney General Jeff Sessions in October 2017. The Sessions memorandum reiterated the positions set out by Trump in an earlierexecutive order, in which the President wrote: It shall be the policy of the executive branch to vigorously enforce Federal law's robust protections for religious freedom. All executive departments and agencies (agencies) shall, to the greatest extent practicable and to the extent permitted by law, respect and protect the freedom of persons and organizations to engage in religious and political speech. President Trump has prioritized enhancing legal protections for religious freedom, including when it comes to obligations placed on faith-based organizations that receive federal funding, the freedom of employers and employees to abstain from practices (particularly in health care) which they feel compromise their religious beliefs, and in calling for an end to the Johnson Amendment, a long-standing provision that bars religious 501 (c)(3) non-profit groups from engaging in electoral activism. In his 2001 executive order establishing the Office of Faith-Based and Community Initiatives, President George W. Bush emphasized that a driving force behind the policy was a desire to "level the playing field" in the disbursement of federal funding, and enhance the funding opportunities available for religious non-profit organizations especially those focused on poverty, addiction, crime and other social issues: The paramount goal is compassionate results, and private and charitable community groups, including religious ones, should have the fullest opportunity permitted by law to compete on a level playing field, so long as they achieve valid public purposes, such as curbing crime, conquering addiction, strengthening families and neighborhoods, and overcoming poverty. This delivery of social services must be results oriented and should value the bedrock principles of pluralism, nondiscrimination, evenhandedness, and neutrality. The Occupy Democrats meme is largely accurate. In May 2018, Trump did indeed establish an initiative within the White House which would give faith-based organizations what the administrationcalled a "voice in the White House." However, the description of the initiative as a "religious office" did not come from the Trump administration itself, and that is not its official name. Furthermore, Trump's 2018 initiative represents significant continuity from predecessor offices set up by George W. Bush in 2001 and Barack Obama in 2009, although the exact focus, workings, and influence of Trump's initiative remain to be seen. On 5 May, the "Being Liberal" Facebook page and web site published an article with the headline "Trump quietly signed an Executive Order allowing government to fund religious groups." This is very misleading, and ignores the fact that the federal government has been providing grants, funding and tax write-offs to religious non-profit organizations for many years, including during the Obama administration. Trump's creation of the White House Faith and Opportunity Initiative did not usher in that state of affairs. Claim: "In May 2018, President Donald Trump established a ""religious office"" to give religious groups a ""voice in government."

A:
"What's true: In May 2018, President Trump established the White House Faith and Opportunity Initiative, in the Executive Office of the President of the United States. The administration said the initiative would give faith-based organizations a ""voice in the White House."" What's false: The description of the initiative as a ""religious office"" did not come from the White House itself, and the meme left out the fact that Trump's 2018 initiative was not a radical new departure, but rather represented significant continuity from earlier similar initiatives in the presidencies of George W. Bush and Barack Obama."
****